Deficiency | Jotup

Jiuzi Holdings Received Nasdaq Notification Letter Related to Late Filing of Annual Report on Form 20-F

Retrieved on:

Friday, March 29, 2024

Annual report, Letter, Deficiency, NEV, Calendar

In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Deficiency Letter to submit a plan to regain compliance with Nasdaq Listing Rules (the “Compliance Plan”).

Key Points:

In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Deficiency Letter to submit a plan to regain compliance with Nasdaq Listing Rules (the “Compliance Plan”).
If Nasdaq accepts the Compliance Plan, Nasdaq may grant the Company an extension until September 10, 2024 to regain compliance.
The Company intends either to file its 2023 Annual Report or submit the Compliance Plan within the prescribed 60-day period.
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

Tritium Receives Nasdaq Delisting Determination

Retrieved on:

Thursday, March 21, 2024

Deficiency, Delisting, Calendar, Hearing, Cryptocurrency

BRISBANE, Australia, March 21, 2024 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Nasdaq: DCFC) (“Tritium” or the “Company”), a global developer and manufacturer of direct current (“DC”) fast chargers for electric vehicles (“EVs”), today announced that on March 15, 2024 the Company received a delisting determination notice (the “Delisting Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”).

Key Points:

BRISBANE, Australia, March 21, 2024 (GLOBE NEWSWIRE) -- Tritium DCFC Limited (Nasdaq: DCFC) (“Tritium” or the “Company”), a global developer and manufacturer of direct current (“DC”) fast chargers for electric vehicles (“EVs”), today announced that on March 15, 2024 the Company received a delisting determination notice (the “Delisting Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”).
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided a period of 180 calendar days, or until April 9, 2024, to regain compliance with the Minimum Bid Price Requirement.
On March 15, 2024, the Company received the subsequent Delisting Notice from Nasdaq notifying the Company that, as of March 15, 2024, the Company's ordinary shares had a closing bid price of $0.10 or less for ten consecutive trading days and that, consistent with Nasdaq Listing Rule 5810(c)(3)(A)(iii), Nasdaq had determined to begin the process to delist the Company's common stock from the Nasdaq Global Market.
On March 22, 2024, the Company intends to submit a request for a hearing before the Nasdaq Hearings Panel to appeal the Delisting Notice.

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

Retrieved on:

Tuesday, March 19, 2024

Ornithine, Brain, PTC Therapeutics, Partnership, Deficiency, Patient, Death, Life, Therapy, Spine, PTC, FDA, AADC, BLA, Food, Pharmaceutical industry

If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.

Key Points:

If approved, Upstaza™ would become the first therapy to treat AADC Deficiency in the United States.
“AADC Deficiency is a devastating rare pediatric movement disorder that causes significant developmental delays and autonomic symptoms starting from birth.
Patients with AADC deficiency are at a high risk of death in the first decade of life,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro.
Through our partnership with PTC, we are demonstrating our commitment to drive progress for the AADC Deficiency community.”

AirNet Announces Receipt of Deficiency Letter from Nasdaq

Retrieved on:

Friday, January 5, 2024

Deficiency, Failure, Letter, Calendar

The Deficiency Letter does not result in the immediate delisting of the Company’s ordinary shares represented by American depositary shares on the Nasdaq Capital Market.

Key Points:

The Deficiency Letter does not result in the immediate delisting of the Company’s ordinary shares represented by American depositary shares on the Nasdaq Capital Market.
The Company has 45 calendar days from the date of the Deficiency Letter, or until February 12, 2024, to submit a plan (the “Compliance Plan”) to Nasdaq to regain compliance with the minimum stockholders’ equity standard.
If the Compliance Plan is accepted by Nasdaq, the Company may be granted a compliance period of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance.
This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

Monday, August 7, 2023

Pharvaris anticipates submitting the results of this nonclinical study to the FDA by the end of 2023.

Key Points:

Pharvaris anticipates submitting the results of this nonclinical study to the FDA by the end of 2023.
R&D expenses were €14.7 million for the quarter ended June 30, 2023, compared to €13.7 million for the quarter ended June 30, 2022.
G&A expenses were €7.8 million for the quarter ended June 30, 2023, compared to €7.7 million for the quarter ended June 30, 2022.
Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

Mullen Trades Above $1 Minimum Bid Price Requirement for 10 Consecutive Days

Retrieved on:

Thursday, May 18, 2023

Calendar, Deficiency, IBN, Auction

(NASDAQ: MULN ) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that its stock has traded above Nasdaq’s $1 minimum bid price requirement for 10 consecutive days.

Key Points:

(NASDAQ: MULN ) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that its stock has traded above Nasdaq’s $1 minimum bid price requirement for 10 consecutive days.
On Sept. 7, 2022, Nasdaq provided notice to the Company that, based on the previous 30 consecutive business days, the Company’s listed common stock no longer met the minimum $1 bid price per share requirement as set forth in Nasdaq Listing Rule 5810(c)(3)(A)(ii) (the “Deficiency”).
On March 8, 2023, Nasdaq approved the Company’s request for a 180-day extension, through Sept. 5, 2023, to meet the $1 minimum bid price requirement.
The Company implemented a reverse stock split to cure the Deficiency, which was effective as of May 4, 2023.

AMGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, May 11, 2023

Investors have until May 12, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until May 12, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
Amgen is one of the world’s largest independent biopharmaceutical companies.
On this news, the price of Amgen common stock fell by an additional 4.3%, further damaging investors.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm

Retrieved on:

Tuesday, May 9, 2023

AMGN, P.C, ASC, IRS, Financial services, Tax, Signature, Government, Deficiency, SVB, Investment, Risk, Silicon, Signature Bank, Environment, News, DFS, SIVB, Audit, Cryptocurrency, Amgen

When the true details entered the market, the lawsuit claims that investors suffered damages.

Key Points:

When the true details entered the market, the lawsuit claims that investors suffered damages.
For more information on the SVB class action go to: https://bespc.com/cases/SIVB
Amgen is one of the world’s largest independent biopharmaceutical companies.
On this news, the price of Amgen common stock fell by an additional 4.3%, further damaging investors.
For more information on the Signature class action go to: https://bespc.com/cases/SBNY

Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

Monday, May 8, 2023

Based on the Company’s current assessment of the ex-U.S. regulatory status and enrollment rates, Pharvaris anticipates announcing top-line data by the end of 2023.

Key Points:

Based on the Company’s current assessment of the ex-U.S. regulatory status and enrollment rates, Pharvaris anticipates announcing top-line data by the end of 2023.
Cash and cash equivalents were €135 million as of March 31, 2023, compared to €162 million for December 31, 2022.
R&D expenses were €13.7 million for the quarter ended March 31, 2023, compared to €13.5 million for the quarter ended March 31, 2022.
G&A expenses were €7.3 million for the quarter ended March 31, 2023, compared to €5.9 million for the quarter ended March 31, 2022.

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

Retrieved on:

Saturday, May 6, 2023

Hereditary angioedema, Bradykinin, Poster, HAE, Angioedema, Deficiency, Medical imaging

ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral presentations and three poster presentations highlighting data from non-clinical and clinical studies of deucrictibant at the 13th C1-inhibitor Deficiency and Angioedema Workshop , being held from May 4-7, 2023, in Budapest, Hungary.

Key Points:

ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral presentations and three poster presentations highlighting data from non-clinical and clinical studies of deucrictibant at the 13th C1-inhibitor Deficiency and Angioedema Workshop , being held from May 4-7, 2023, in Budapest, Hungary.
“Today, two sequential presentations showed how PHVS416 (immediate-release deucrictibant capsules) provided symptom relief and resolution in the treatment of HAE attacks using the doses projected through the bradykinin challenge, our in vivo surrogate marker model,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris.
“The RAPIDe-1 study showed consistent and clinically meaningful results across all endpoints supporting the further development of PHVS416 as a potential on-demand therapy for HAE.
We plan to leverage these findings to prepare for RAPIDe-3, our Phase 3 clinical study evaluating PHVS416 for the treatment of on-demand HAE attacks.”
Anne Lesage, Ph.D., Chief Early Development Officer of Pharvaris, added, “The outcomes of the cardiovascular assessments in non-clinical studies, combined with the data from our clinical studies to date, support the cardiovascular tolerability and safety profile of deucrictibant for the potential treatment of HAE and other bradykinin-mediated diseases with unmet need.”
Presentation details and key data highlights include: